1
|
Nagamatsu D, Ando S, Fujimura Y, Miyano T, Sugita K, Ueda H. Formation of Hemihydrate Crystal form Overcomes Milling Issue Induced by Exposed Functional Groups on Cleavage Plane for a Y5 Receptor Antagonist of Neuropeptide Y. J Pharm Sci 2023; 112:2516-2523. [PMID: 37100203 DOI: 10.1016/j.xphs.2023.04.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2023] [Revised: 04/20/2023] [Accepted: 04/20/2023] [Indexed: 04/28/2023]
Abstract
This study aimed to investigate the crystal forms of an originally designed Y5 receptor antagonist of neuropeptide Y. Polymorphic screening was performed via solvent evaporation and slurry conversion using various solvents. The obtained crystal forms α, β, and γ were characterized by X-ray powder diffraction analysis. Thermal analysis determined that forms α, β, and γ were hemihydrate, metastable and stable forms, respectively; the hemihydrate and the stable forms were candidates. To arrange the particle size, forms α and γ were subjected to jet milling. However, form γ could not be milled because of powder stiction to the apparatus, whereas form α could be. To investigate this mechanism, single-crystal X-ray diffraction analysis was performed. The crystal structure of form γ was characterized by two-dimensional hydrogen bonding between neighboring molecules. This revealed that the functional groups forming hydrogen bonds were exposed on the cleavage plane of form γ. The three-dimensional hydrogen-bonding network with water stabilized the hemihydrate form, α. These results indicate that the hydrogen bondable groups exposed on the cleavage plane of form γ should result in stiction of the powder and adherence to the apparatus. It was concluded that crystal conversion is a method to overcome the milling issue.
Collapse
Affiliation(s)
- Daiki Nagamatsu
- Laboratory for Medicinal Chemistry Research, Shionogi & Co., Ltd., Osaka, 561-0825, Japan
| | - Shigeru Ando
- Sustainability Management Department, Shionogi & Co., Ltd., Osaka, 541-0045, Japan
| | - Yuko Fujimura
- Intellectual Property Department, Shionogi & Co., Ltd., Osaka, 541-0045, Japan
| | - Tetsuya Miyano
- Laboratory for Medicinal Chemistry Research, Shionogi & Co., Ltd., Osaka, 561-0825, Japan
| | - Katsuji Sugita
- Laboratory for Medicinal Chemistry Research, Shionogi & Co., Ltd., Osaka, 561-0825, Japan
| | - Hiroshi Ueda
- Analysis and Evaluation Laboratory, Shionogi & Co., Ltd., Osaka, 561-0825, Japan.
| |
Collapse
|
2
|
Fujiu M, Yokoo K, Sato J, Shibuya S, Komano K, Kusano H, Sato S, Aoki T, Kohira N, Kanazawa S, Watari R, Kawachi T, Hirakawa Y, Nagamatsu D, Kashiwagi E, Maki H, Yamawaki K. Discovery of 2-Sulfinyl-Diazabicyclooctane Derivatives, Potential Oral β-Lactamase Inhibitors for Infections Caused by Serine β-Lactamase-Producing Enterobacterales. J Med Chem 2021; 64:9496-9512. [PMID: 34143627 DOI: 10.1021/acs.jmedchem.1c00799] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Coadministration of β-lactam and β-lactamase inhibitor (BLI) is one of the well-established therapeutic measures for bacterial infections caused by β-lactam-resistant Gram-negative bacteria, whereas we have only two options for orally active BLI, clavulanic acid and sulbactam. Furthermore, these BLIs are losing their clinical usefulness because of the spread of new β-lactamases, including extended-spectrum β-lactamases (ESBLs) belonging to class A β-lactamases, class C and D β-lactamases, and carbapenemases, which are hardly or not inhibited by these classical BLIs. From the viewpoints of medical cost and burden of healthcare personnel, oral therapy offers many advantages. In our search for novel diazabicyclooctane (DBO) BLIs possessing a thio-functional group at the C2 position, we discovered a 2-sulfinyl-DBO derivative (2), which restores the antibacterial activities of an orally available third-generation cephalosporin, ceftibuten (CTB), against various serine β-lactamase-producing strains including carbapenem-resistant Enterobacteriaceae (CRE). It can be orally absorbed via the ester prodrug modification and exhibits in vivo efficacy in a combination with CTB.
Collapse
Affiliation(s)
- Motohiro Fujiu
- Shionogi Pharmaceutical Research Center, 3-1-1, Futaba-cho, Toyonaka-shi, Osaka 561-0825, Japan
| | - Katsuki Yokoo
- Shionogi Pharmaceutical Research Center, 3-1-1, Futaba-cho, Toyonaka-shi, Osaka 561-0825, Japan
| | - Jun Sato
- Shionogi Pharmaceutical Research Center, 3-1-1, Futaba-cho, Toyonaka-shi, Osaka 561-0825, Japan
| | - Satoru Shibuya
- Shionogi Pharmaceutical Research Center, 3-1-1, Futaba-cho, Toyonaka-shi, Osaka 561-0825, Japan
| | - Kazuo Komano
- Shionogi Pharmaceutical Research Center, 3-1-1, Futaba-cho, Toyonaka-shi, Osaka 561-0825, Japan
| | - Hiroki Kusano
- Shionogi Pharmaceutical Research Center, 3-1-1, Futaba-cho, Toyonaka-shi, Osaka 561-0825, Japan
| | - Soichiro Sato
- Shionogi Pharmaceutical Research Center, 3-1-1, Futaba-cho, Toyonaka-shi, Osaka 561-0825, Japan
| | - Toshiaki Aoki
- Shionogi CMC Research Innovation Center, 2-1-3, Kuiseterajima, Amagasaki-shi, Hyogo 660-0813, Japan
| | - Naoki Kohira
- Shionogi Pharmaceutical Research Center, 3-1-1, Futaba-cho, Toyonaka-shi, Osaka 561-0825, Japan
| | - Sachi Kanazawa
- Shionogi Pharmaceutical Research Center, 3-1-1, Futaba-cho, Toyonaka-shi, Osaka 561-0825, Japan
| | - Ryosuke Watari
- Shionogi Pharmaceutical Research Center, 3-1-1, Futaba-cho, Toyonaka-shi, Osaka 561-0825, Japan
| | - Tomoyuki Kawachi
- Shionogi Pharmaceutical Research Center, 3-1-1, Futaba-cho, Toyonaka-shi, Osaka 561-0825, Japan
| | - Yuya Hirakawa
- Shionogi Pharmaceutical Research Center, 3-1-1, Futaba-cho, Toyonaka-shi, Osaka 561-0825, Japan
| | - Daiki Nagamatsu
- Shionogi Pharmaceutical Research Center, 3-1-1, Futaba-cho, Toyonaka-shi, Osaka 561-0825, Japan
| | - Emi Kashiwagi
- Shionogi Pharmaceutical Research Center, 3-1-1, Futaba-cho, Toyonaka-shi, Osaka 561-0825, Japan
| | - Hideki Maki
- Shionogi Pharmaceutical Research Center, 3-1-1, Futaba-cho, Toyonaka-shi, Osaka 561-0825, Japan
| | - Kenji Yamawaki
- Shionogi Pharmaceutical Research Center, 3-1-1, Futaba-cho, Toyonaka-shi, Osaka 561-0825, Japan
| |
Collapse
|
3
|
Tsuno N, Yukimasa A, Yoshida O, Suzuki S, Nakai H, Ogawa T, Fujiu M, Takaya K, Nozu A, Yamaguchi H, Matsuda H, Funaki S, Yamanada N, Tanimura M, Nagamatsu D, Asaki T, Horita N, Yamamoto M, Hinata M, Soga M, Imai M, Morioka Y, Kanemasa T, Sakaguchi G, Iso Y. Pharmacological evaluation of novel (6-aminopyridin-3-yl)(4-(pyridin-2-yl)piperazin-1-yl) methanone derivatives as TRPV4 antagonists for the treatment of pain. Bioorg Med Chem 2017; 25:2177-2190. [PMID: 28284871 DOI: 10.1016/j.bmc.2017.02.047] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2016] [Revised: 02/13/2017] [Accepted: 02/15/2017] [Indexed: 01/08/2023]
Abstract
A novel series of (6-aminopyridin-3-yl)(4-(pyridin-2-yl)piperazin-1-yl) methanone derivatives were identified as selective transient receptor potential vanilloid 4 (TRPV4) channel antagonist and showed analgesic effect in Freund's Complete Adjuvant (FCA) induced mechanical hyperalgesia model in guinea pig and rat. Modification of right part based on the compound 16d which was disclosed in our previous communication led to the identification of compound 26i as a flagship compound. In this paper, we described the details about design, synthesis and structure-activity relationship (SAR) analysis at right and left part of these derivatives (Fig. 1).
Collapse
Affiliation(s)
- Naoki Tsuno
- Medicinal Chemistry Research Laboratory, Shionogi & Co., Ltd, Japan.
| | - Akira Yukimasa
- Medicinal Chemistry Research Laboratory, Shionogi & Co., Ltd, Japan
| | - Osamu Yoshida
- Medicinal Chemistry Research Laboratory, Shionogi & Co., Ltd, Japan
| | - Shinji Suzuki
- Medicinal Chemistry Research Laboratory, Shionogi & Co., Ltd, Japan
| | - Hiromi Nakai
- Medicinal Chemistry Research Laboratory, Shionogi & Co., Ltd, Japan
| | - Tomoyuki Ogawa
- Medicinal Chemistry Research Laboratory, Shionogi & Co., Ltd, Japan
| | - Motohiro Fujiu
- Medicinal Chemistry Research Laboratory, Shionogi & Co., Ltd, Japan
| | - Kenji Takaya
- Medicinal Chemistry Research Laboratory, Shionogi & Co., Ltd, Japan
| | - Azusa Nozu
- Medicinal Chemistry Research Laboratory, Shionogi & Co., Ltd, Japan
| | - Hiroki Yamaguchi
- Medicinal Chemistry Research Laboratory, Shionogi & Co., Ltd, Japan
| | | | - Satoko Funaki
- Research Laboratory for Development, Shionogi & Co., Ltd, Japan
| | - Natsue Yamanada
- Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd, Japan
| | - Miki Tanimura
- Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd, Japan
| | - Daiki Nagamatsu
- Research Laboratory for Development, Shionogi & Co., Ltd, Japan
| | - Toshiyuki Asaki
- Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd, Japan
| | | | - Miyuki Yamamoto
- Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd, Japan
| | - Mikie Hinata
- Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd, Japan
| | - Masahiko Soga
- Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd, Japan
| | - Masayuki Imai
- Global Innovation Office, Shionogi & Co., Ltd, Japan
| | - Yasuhide Morioka
- Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd, Japan
| | - Toshiyuki Kanemasa
- Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd, Japan
| | | | - Yasuyoshi Iso
- IMP Manufacturing Center, CMC R&D Division, Shionogi & Co., Ltd, Japan
| |
Collapse
|
4
|
Nagamatsu D, Sato N, Takiyama H. Estimation of Temperature Dependency on Crystallization Using the Critical Supersaturation Ratio (<i>S</i><sup><i>c</i></sup>). J Chem Eng Japan / JCEJ 2017. [DOI: 10.1252/jcej.16we274] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Daiki Nagamatsu
- Innovative Drug Discovery Research Laboratories, Shionogi & Co., Ltd
- Department of Chemical Engineering, Tokyo University of Agriculture and Technology (TUAT)
| | - Norihito Sato
- Innovative Drug Discovery Research Laboratories, Shionogi & Co., Ltd
| | - Hiroshi Takiyama
- Department of Chemical Engineering, Tokyo University of Agriculture and Technology (TUAT)
| |
Collapse
|
5
|
Tsuno N, Yukimasa A, Yoshida O, Ichihashi Y, Inoue T, Ueno T, Yamaguchi H, Matsuda H, Funaki S, Yamanada N, Tanimura M, Nagamatsu D, Nishimura Y, Ito T, Soga M, Horita N, Yamamoto M, Hinata M, Imai M, Morioka Y, Kanemasa T, Sakaguchi G, Iso Y. Discovery of novel 2′,4′-dimethyl-[4,5′-bithiazol]-2-yl amino derivatives as orally bioavailable TRPV4 antagonists for the treatment of pain: Part 1. Bioorg Med Chem Lett 2016; 26:4930-4935. [DOI: 10.1016/j.bmcl.2016.09.013] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2016] [Revised: 08/30/2016] [Accepted: 09/06/2016] [Indexed: 11/26/2022]
|
6
|
Tsuno N, Yukimasa A, Yoshida O, Suzuki S, Nakai H, Ogawa T, Fujiu M, Takaya K, Nozu A, Yamaguchi H, Matsuda H, Funaki S, Nishimura Y, Ito T, Nagamatsu D, Asaki T, Horita N, Yamamoto M, Hinata M, Soga M, Imai M, Morioka Y, Kanemasa T, Sakaguchi G, Iso Y. Discovery of novel 2′,4′-dimethyl-[4,5′-bithiazol]-2-yl amino derivatives as orally bioavailable TRPV4 antagonists for the treatment of pain: Part 2. Bioorg Med Chem Lett 2016; 26:4936-4941. [DOI: 10.1016/j.bmcl.2016.09.014] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2016] [Revised: 08/30/2016] [Accepted: 09/06/2016] [Indexed: 12/12/2022]
|
7
|
Abe I, Nagamatsu D, Nakahara T, Fabian G. Separation of Warfarin Enantiomers by Capillary Gas Chromatography with Chiral Stationary Phase. CHEM LETT 2004. [DOI: 10.1246/cl.2004.260] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|